Human Antibodies for Immuno-Histochemical Analysis of Prostate CancerTechnology #2739
Questions about this technology? Ask a Technology Manager
“Lead Inventor: Cory Abate-Shen, Ph.D.
Prostate Cancer Detected Early is Key to Successful Treatment Prostate cancer is the most common cancer in men after skin cancer. Early detection of cancers is key to successful treatment. Thus there is a need for improved detection methods. Nkx3.1 is involved cancer initiation, making it a useful marker for the detection and characterization of carcinomas. This technology provides new polyclonal antibodies for immuno-histochemical analysis of prostate carcinoma tissues.
Prostate Carcinoma Tissues in Mice Suggest Specific Genes Involved in Cancer Initiation Nkx3.1 homeobox gene has restricted expression in the prostate and an essential role in prostate differentiation and function. Loss of function of Nkx3.1 in mice results in prostatic epithelial hyperplasia and dysplasia as a correlate of aging, and Nkx3.1 heterozygotes display a similar although less severe phenotype than homozygotes, indicating haploinsufficiency. The relevance of NKX3.1 for human prostate cancer has been suggested by its localization to chromosomal region 8p21 (8, 9), which undergoes loss of heterozygosity (LOH) in »80% of prostate cancers. Notably, 8p21 LOH represents an early event in prostate carcinogenesis, because it occurs at high frequency in PIN, suggesting that genes within this region are involved in cancer initiation.
Applications: • Immuno-histochemical analysis of prostate carcinomas tissues in humans • Detection and characterization of prostate cancer in humans
Advantages: • Using antibodies directed to a protein involved in cancer initiation will allow for better characterization of cancer cells in the early stages of cancer
Patent Status: Copyright
Licensing Status: Copyright / Material available for Express Licensing New Human Antibodies for Immuno-histochemical Analysis of Prostate Cancer